Search results for " Outcomes."

showing 10 items of 345 documents

A model for a national clinical final examination in the Swedish bachelor programme in nursing

2011

Aim To describe the development and evaluation of a model for a national clinical final examination in the bachelor nursing education.Background After the transfer of nursing education to the academy, concerns have been raised among nurses, nurse leaders, lecturers and researchers about the nursing students clinical competence at the entrance to professional life.Methods During 2003 to 2005, a collaborative project was carried out between four universities and adjunctive health-care areas supplying clinical placements in Sweden. A two-part examination was agreed upon comprising a written theoretical test and a bedside test. An assessment tool for the bedside test was created. Nursing studen…

Oncology nursingTeam nursingNursingLeadership and Managementbusiness.industryOccupational health nursingNursing researchMedicineNurse educationNursing managementbusinessPrimary nursingNursing Outcomes ClassificationJournal of Nursing Management
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Permanent seed brachytherapy for clinically localized prostate cancer: long-term outcomes in a 700 patient cohort.

2015

Abstract Purpose Few large European studies have evaluated long-term outcomes for permanent prostate brachytherapy (PPB) as monotherapy for clinically localized prostate cancer. The objective of the present study was to evaluate long-term survival in this patient profile. Methods and Materials Retrospective study of 700 patients who underwent transperineal ultrasound-guided iodine-125 PPB (145 Gy) between January 2000 and July 2012. Median age was 64.8 years (range, 35–79). Most patients (638 of 700; 91%) had low-risk disease (D'Amico criteria). Eighty-five patients (12%) received hormonal treatment. Overall survival, cause-specific survival, and biochemical relapse–free survival were calcu…

OncologyAdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBrachytherapyBrachytherapyUrologyPermanent prostate brachytherapyKaplan-Meier EstimateCohort StudiesIodine RadioisotopesProstate cancerInternal medicineOverall survivalmedicineLong term outcomesHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesAged 80 and overbusiness.industryProstatic NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseConfidence intervalTreatment OutcomeOncologyCohortbusinessFollow-Up StudiesBrachytherapy
researchProduct

Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer

2015

Abstract This review considers the potential utility of positron emission tomography (PET) tracers in the setting of response monitoring in breast cancer, with a special emphasis on glucose metabolic changes assessed with 18F-fluorodeoxyglucose (FDG). In the neoadjuvant setting of breast cancer, the metabolic response can predict the final complete pathologic response after the first cycles of chemotherapy. Because tumor metabolic behavior highly depends on cancer subtype, studies are ongoing to define the optimal metabolic criteria of tumor response in each subtype. The recent multicentric randomized AVATAXHER trial has suggested, in the human epidermal growth factor 2-positive subtype, a …

OncologyCancer Researchmedicine.medical_specialtyPathologyResponse to therapyReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineHealth outcomesTumor response030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineBreast CancerHumansMedicineskin and connective tissue diseasesComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryTumor biologyCancerPrognosismedicine.disease3. Good healthRadiographyOncologyPositron emission tomographyPositron-Emission Tomography030220 oncology & carcinogenesisFemalebusiness
researchProduct

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA)…

2020

Introduction: DARA is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. In the phase 3 ALCYONE study (median follow-up of 40.1 months), DARA in combination with VMP (D-VMP) reduced the risk of disease progression or death by 58% versus VMP alone (median 36.4 vs 19.3 months; HR, 0.42; 95% CI, 0.34-0.51; P<0.0001) and demonstrated a significant overall survival (OS) benefit (median not reached in either group; HR, 0.60; 95% CI, 0.46-0.80; P=0.0003) for patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). Here, we report the results of a subgroup analysis examining long-term efficacy outcome…

OncologyHealth related quality of lifeMelphalanmedicine.medical_specialtybusiness.industryBortezomibImmunologyDaratumumabCell BiologyHematologyDaraBiochemistryPrednisoneInternal medicinemedicineLong term outcomesbusinessmedicine.drugBlood
researchProduct

Fertility sparing treatments in endometrial cancer patients: the potential role of the new molecular classification

2021

Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection…

Oncologymedicine.medical_specialtyQH301-705.5obstetric outcomesReviewHysteroscopyCatalysisFertility sparing surgeryInorganic ChemistryMolecular classificationPrognostic classificationInternal medicineCancer genomeOutcome Assessment Health CaremedicineHumansmolecular biologyPhysical and Theoretical ChemistryBiology (General)QD1-999SpectroscopyPregnancybusiness.industryEndometrial cancerOrganic ChemistryFertility PreservationCancerGeneral Medicinemedicine.diseaseEndometrial cancer; Fertility sparing; Molecular biology; Obstetric outcomes; PregnancyCombined Modality Therapyfertility sparingEndometrial NeoplasmsComputer Science Applicationsendometrial cancer; molecular biology; fertility sparing; obstetric outcomes; pregnancyChemistryFertilityGynecological malignancyendometrial cancerFemalepregnancyProgestinsbusinessOrgan Sparing Treatments
researchProduct

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 …

2019

Introduction In MCL, progression-free survival (PFS) generally declines with each successive line of chemoimmunotherapy (CIT). We have previously published that with ibrutinib, a first-in-class oral inhibitor of Bruton's tyrosine kinase and a standard of care treatment (tx) for R/R MCL, median PFS exceeded 2 years (yrs) when used at first relapse (Rule S, et al. Haematologica. 2018;104:e211-e214). Here we present an updated pooled analysis with 15 months (mos) of additional follow-up, and for the first time, a comparison of outcomes with ibrutinib versus the prior regimen. Methods Patients (pts) enrolled in SPARK (MCL2001; NCT01599949), RAY (MCL3001; NCT01646021), and PCYC-1104 (NCT01236391…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryCytokine release syndromechemistry.chemical_compoundRegimenPooled analysischemistryInternal medicineIbrutinibRelapsed refractoryLong term outcomesmedicineVindesineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy

2014

Francesco Saverio Mennini,1,2 Andrea Marcellusi,1,3 Massimo Andreoni,4 Antonio Gasbarrini,5 Salvatore Salomone,6 Antonio Craxì71Centre for Economic and International Studies (CEIS) – Economic Evaluation and HTA (EEHTA) Faculty of Economics, University of Rome Tor Vergata, Rome, Italy; 2Institute of Leadership and Management in Health, Kingston University, London, UK; 3Department of Demography, University of Rome La Sapienza, Rome, Italy; 4Department of Public Health and Cell Biology, School of Medicine, University of Rome Tor Vergata, Rome, Italy; 5Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rome, Italy; 6Department of…

Operations researchHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAEconomics Econometrics and Finance (miscellaneous)forecastcost of illnessmacromolecular substancesmedicine.disease_causeChronic hepatitisEnvironmental healthCost of illnessMedicineHealth policyOriginal Researchlcsh:R5-920business.industryHealth Policylcsh:RM1-950Health services researchvirus diseasesSettore SECS-S/04 - Demografianew HCV treatmentClinicoEconomics and Outcomes Researchlcsh:Therapeutics. Pharmacologychronic hepatitishepatitis Cbusinesslcsh:Medicine (General)ClinicoEconomics and Outcomes Research
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Digital Learning Interventions in Higher Education: A Scoping Review.

2020

Abstract This scoping review was undertaken to synthesize and describe research related to digital learning interventions in higher education, focusing on technological outcomes. Five electronic databases were searched, and 86 articles were included in the review. The data related to positive and negative technological outcomes and authors’ suggestions were analyzed using inductive content analysis. The articles represented six disciplines across six continents and included quantitative (n = 65), qualitative (n = 3), and mixed-methods (n = 18) intervention studies. For positive technological outcomes, digital formats of learning were considered effective and participatory forms of learning …

Organizational Behavior and Human Resource ManagementScoping reviewInternationality020205 medical informaticsHigher educationUniversitiesStrategy and ManagementMEDLINEPsychological interventionPharmaceutical Science02 engineering and technology03 medical and health sciencesDrug Discovery0202 electrical engineering electronic engineering information engineeringHumansLearningHigher educationDigital learningStudentsDigital learningMarketingPharmacologyMedical education030504 nursingbusiness.industryIntervention studyEducational TechnologyCitizen journalismTechnological outcomesViewpointsIntervention studiesContent analysis0305 other medical sciencebusinessPsychologyComputers, informatics, nursing : CIN
researchProduct